Changes in brain function during negative emotion processing in the long-term course of depression

Verena Enneking*, Melissa Klug*, Tiana Borgers, Katharina Dohm, Dominik Grotegerd, Lisa Marie Frankenberger, Carina Hülsmann, Hannah Lemke, Susanne Meinert, Elisabeth J. Leehr, Nils Opel, Janik Gottermann, Maike Richter, Lena Waltemate, Joscha Böhlein, Lisa Sindermann, Jonathan Repple, Jochen Bauer, Mareike Thomas, Udo Dannlowski* and Ronny Redlich*

Background
Relapses in major depression are frequent and are associated with a high burden of disease. Although short-term studies suggest a normalisation of depression-associated brain functional alterations directly after treatment, long-term investigations are sparse.

Aims
To examine brain function during negative emotion processing in association with course of illness over a 2-year span.

Method
In this prospective case–control study, 72 in-patients with current depression and 42 healthy controls were investigated during a negative emotional face processing paradigm, at baseline and after 2 years. According to their course of illness during the study interval, patients were divided into subgroups (n = 25 no-relapse, n = 47 relapse). The differential changes in brain activity were investigated by a group × time analysis of covariance for the amygdala, hippocampus, insula and at whole-brain level.

Results
A significant relapse × time interaction emerged within the amygdala (P_{TFCE-FWE} = 0.011), insula (P_{TFCE-FWE} = 0.001) and at the whole-brain level mainly in the temporal and prefrontal cortex (P_{TFCE} = 0.027), resulting from activity increases within the no-relapse group, whereas in the relapse group, activity decreased during the study interval. At baseline, the no-relapse group showed amygdala, hippocampus and insula hypoactivity compared with healthy controls and the relapse group.

Conclusions
This study reveals course of illness-associated activity changes in emotion processing areas. Patients in full remission show a normalisation of their baseline hypo-responsiveness to the activation level of healthy controls after 2 years. Brain function during emotion processing could further serve as a potential predictive marker for future relapse.

Keywords
Depressive disorders; imaging; relapse; emotion processing; limbic system.

Copyright and usage
© The Author(s), 2022. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Major depressive disorder is one of the most common and burdening mental diseases worldwide, and is associated with a mood-congruent bias in emotion processing. The course of the illness shows a large interindividual heterogeneity, varying from a single lifetime depressive episode to recurrent or ongoing episodes, with the risk for a future relapse being increased with each episode. In fact, it is the course of illness over years that determines chronic disease burden and loss of functioning. The neural correlates that underlie depressive relapses are of high psychosocial and economic interest, albeit poorly understood. Prospective neuroimaging studies could help to understand how disease progression affects the brain function during emotion processing, and identify patients at high risk of relapse who could benefit from applying intensified treatments and prevention strategies.

Neural correlates of negative emotion processing in depression
On the neural level, the mood-congruent bias in emotion processing in depression has been linked to a dysfunction of a fronto-limbic network, with a hyperactivity of (para-)limbic regions – such as the amygdala, hippocampus and insula – and a hypoactivity of prefrontal regions, including the dorsomedial and dorsolateral prefrontal cortex (DLPFC), in response to negative stimuli. So far, longitudinal functional magnetic resonance imaging (fMRI) studies mainly focused on short-term effects of treatments for depression on brain function, mostly indicating a normalisation of depression-associated alterations in brain activity after successful treatment; for example, a reduction of pre-treatment amygdala and hippocampus hyperactivity during processing of sad or fearful faces was reported after treatment with antidepressants and electroconvulsive therapy. Regarding the insula, the state of research is less clear, with some studies indicating activity increases to negative stimuli after treatment, and other studies pointing to decreases.

Long-term fMRI investigations
Only two fMRI studies examined changes in brain function in patients with depression during emotion processing covering more than 1 year. They revealed that in remitted patients, insula activity in response to positive stimuli was reduced after 2 years, and symptomatic improvement was associated with increased amygdala and hippocampus activity in response to positive and negative words. However, regarding negative stimuli, these results seem to stand in contrast to evidence of short-term treatment studies described above, which mainly showed a reduction in limbic hyperactivity. As Opmeer et al. found no activity changes for negative stimuli, there is a need to further investigate the long-term changes in brain function during negative stimuli processing.

Furthermore, the study of Ai et al. suggested that brain functional changes were a result of remission status rather than...
of duration of depression during the study interval, whereas Opmeer et al.\textsuperscript{12} did not examine the influence of duration in depression or relapses during the study interval on their results. Therefore, in depression, the impact of course of illness and remission status on brain functional changes is still unclear and remains to be explored.

**Aims of the study**

The present study was designed to examine course of illness-dependent changes in negative emotion processing in a prospective approach. As the few longitudinal studies that examined brain functional changes over the long-term course of depression pointed to changes in the amygdala, hippocampus and insula as parts of brain circuits relevant for emotion processing and salience detection, a particular focus was placed on these regions. The objectives were as follows: (a) to investigate long-term changes in brain function during negative emotion processing and its dependence on the course of illness and remission status in patients with depression, in a prospective naturalistic design; (b) to subsequently control for the influence of medication dose and psychotherapy on brain function; and (c) to identify baseline differences in brain activity between patients with depression with different course of illness (full remission versus recurrent or ongoing depression).

**Participants and study design**

In this case–control study, participants were investigated as part of an ongoing study of the Münster Neuroimaging Cohort from May 2010 to June 2015, and were reassessed from September 2012 to an ongoing study of the Münster Neuroimaging Cohort from May 2021.\textsuperscript{223) See Supplementary Fig. 1 available at https://doi.org/10.1192/bjp.2021.223.}

At baseline and follow-up, participants underwent fMRI during processing of negative emotional faces. Furthermore, the structured clinical interview for the DSM-IV\textsuperscript{11} and the Hamilton Rating Scale for Depression (HRSD)\textsuperscript{12} were conducted by trained clinical raters. Course of illness was assessed at baseline and follow-up (for a visualisation of exclusion process, see Supplementary Methods 1.1). For details on psychopharmacological medication intake, see Supplementary Table 1.

The final sample comprised 72 patients with depression and 42 healthy controls. Participants’ characteristics are summarised in Table 1. There was an overlap of 53 patients with depression and 31 healthy controls with a sample reported in one of our earlier studies investigating long-term morphological brain changes.\textsuperscript{13} The patient group was further divided into two subgroups following a previously published protocol:\textsuperscript{14,15} patients who were in full remission at follow-up and who did not experience any further depressive episode after baseline (no-relapse group, \(n = 25\)), and patients who suffered from ongoing depression since baseline or experienced at least one further depressive episode according to the DSM-IV\textsuperscript{15} after baseline (relapse group, \(n = 47\)).

**fMRI methods**

fMRI data acquisition and preprocessing followed previously published protocols.\textsuperscript{16,17} For details regarding the fMRI paradigm, data acquisition and preprocessing methods, see Supplementary Methods 1.2–1.4 and previous works.\textsuperscript{16–18}

Briefly, T2* functional data were acquired with a single-shot echoplanar sequence with a 3T scanner (Gyrosan Intera 3T, Philips Medical System, Best, The Netherlands). The fMRI paradigm was a modified version of the face-matching task described by Hariri et al.\textsuperscript{18} It consisted of four blocks of an emotional face processing task and five blocks of a sensorimotor control task. Faces were derived from the Ekman and Friesen stimulus set\textsuperscript{19} and expressed either anger or fear (Supplementary Fig. 2(a)), whereas the control task consisted of geometric shapes (circles or ellipses, see Supplementary Fig. 2(b)).

Onsets and durations of the two experimental conditions (faces and shapes) were modelled with a canonical hemodynamic response function in the context of the general linear model. The model was corrected for serial correlations and a high-pass filter of 128 s was applied to remove low-frequency noise. The six movement parameters from the realignment step were further entered as nuisance covariates. For each participant and measurement, an individual contrast image (faces > shapes) was generated in each of the previously published protocols.\textsuperscript{16,17} For details regarding the fMRI analysis of fMRI methods, see Supplementary Methods 1.2–1.4 and previous works.\textsuperscript{16–18}

Region-of-interest analyses were performed based on the faces > shapes contrast.

**Statistical analyses**

Analyses of demographic and clinical data were performed with SPSS Statistics (version 25.0 for Windows; IBM Corporation). Second-level analyses of fMRI data were conducted with statistical parametric mapping software (SPM12, version 6685 for MATLAB on Ubuntu; Wellcome Department of Cognitive Neurology, London, UK; http://www.fil.ion.ucl.ac.uk/spm). Significance thresholds for multiple testing were obtained at the cluster-level by threshold-free cluster enhancement (TFCE), using the TFCE toolbox (version 223; Structural Brain Mapping Group, Jena, Germany; http://dbm.neuro.uni-jena.de/tfce) implemented in SPM12. We established a family-wise error (FWE)-corrected threshold of \(P < 0.05\), obtained by 10 000 permutations per test. All second-level analyses were performed based on the faces > shapes contrast.

**Region-of-interest analyses**

First, all second-level analyses were performed in a region-of-interest (ROI) approach, based on masked voxel-wise analyses using small volume correction as implemented in the TFCE toolbox in...
Enneking et al.

Enneking et al. investigated the relapse prediction based on baseline brain functional data compared with clinical data (Supplementary Methods 1.5.2) and (c) effects of medication dose and psychotherapy on changes in brain function (Supplementary Methods 1.5.1), (b) relapse prediction based on baseline brain functional data compared with clinical data (Supplementary Methods 1.5.2) and (c) effects of remission status on follow-up brain activity (Supplementary Methods 1.5.3).

Methods 1.5.3).

Additional analyses

The Supplementary Methods provide a description of our additional analyses on (a) effects of medication dose and psychotherapy on changes in brain function (Supplementary Methods 1.5.1), (b) relapse prediction based on baseline brain functional data compared with clinical data (Supplementary Methods 1.5.2) and (c) effects of remission status on follow-up brain activity (Supplementary Methods 1.5.3).

Whole-brain analyses

All second-level analyses for the 3 × 2 ANCOVA described for the ROI analyses were also performed at the whole-brain level.

Additional analyses

The Supplementary Methods provide a description of our additional analyses on (a) effects of medication dose and psychotherapy on changes in brain function (Supplementary Methods 1.5.1), (b) relapse prediction based on baseline brain functional data compared with clinical data (Supplementary Methods 1.5.2) and (c) effects of remission status on follow-up brain activity (Supplementary Methods 1.5.3).

Table 1

| Variable                                      | Patients with depression and relapse, n = 47 | Patients with depression and no-relapse, n = 25 | Healthy controls, n = 42 | P-valuea | P-valueb |
|-----------------------------------------------|---------------------------------------------|-----------------------------------------------|--------------------------|---------|---------|
| Interscan interval, years                     | 2.00 (0.31)                                 | 2.21 (0.21)                                   | 2.34 (0.31)              | 0.07    | 0.91    |
| Sociodemographic characteristics             |                                             |                                              |                          |         |         |
| Age                                           | 37.5 (12.4)                                 | 32.8 (10.6)                                   | 37.4 (9.1)               | 0.17    | 0.11    |
| Gender (female/male), number of patients      | 27/20                                       | 13/12                                        | 19/23                    | 0.52    | 0.66    |
| Symptom severity                              |                                             |                                              |                          |         |         |
| HRSD baseline                                 | 23.2 (4.9)                                  | 22.6 (3.6)                                   | 0.5 (0.8)                | <0.001  | 0.59    |
| HRSD follow-up                                | 12.7 (7.7)                                  | 4.0 (4.3)                                    | 1.1 (1.9)                | <0.001  | <0.001  |
| Clinical characteristics at baseline          |                                             |                                              |                          |         |         |
| Number of depressive episodes before baseline | 4.9 (6.6)                                   | 3.4 (4.7)                                    | –                        | –       | 0.33    |
| Number of in-patient treatments before baseline | 2.2 (1.7)                       | 1.4 (1.9)                                    | –                        | –       | 0.009   |
| Duration of in-patient treatment before baseline, months | 2.6 (3.3)                              | 1.5 (2.4)                                    | –                        | –       | 0.17    |
| Cumulative duration of depression before baseline, months | 36.2 (37.2)                          | 12.7 (12.3)                                   | –                        | –       | <0.001  |
| Acute comorbidity (yes/no), number of patients | 19/28                                      | 6/19                                         | –                        | –       | 0.16    |
| Acute comorbid anxiety disorder (yes/no), number of patients | 13/34                                      | 5/20                                         | –                        | –       | 0.48    |
| Clinical characteristics at follow-up         |                                             |                                              |                          |         |         |
| Number of depressive episodes between baseline and follow-up | 1.4 (0.8)                              | 0.0 (0.0)                                    | –                        | –       | <0.001  |
| Number of in-patient treatments between baseline and follow-up | 0.6 (0.7)                              | 0.0 (0.0)                                    | –                        | –       | <0.001  |
| Remission status at follow-up (no remission/partial remission/full remission), number of patients | 14/19/14                                | 0/0/25                                       | –                        | –       | <0.001  |
| Acute comorbidity (yes/no), number of patients | 22/25                                      | 2/23                                         | –                        | –       | <0.001  |
| Acute comorbid anxiety disorder (yes/no), number of patients | 16/31                                      | 2/23                                         | –                        | –       | 0.02    |
| Medical treatment                             |                                             |                                              |                          |         |         |
| Number of patients under psychopharmacological medication at baseline (yes/no) | 44/3                                       | 24/1                                         | –                        | –       | 0.67    |
| Number of patients under psychopharmacological medication at follow-up (yes/no) | 38/9                                       | 13/12                                        | –                        | –       | 0.01    |
| Medication load index at baseline             | 2.2 (1.4)                                  | 1.9 (0.9)                                    | –                        | –       | 0.34    |
| Medication load index at follow-up            | 1.7 (1.4)                                  | 0.9 (1.1)                                    | –                        | –       | 0.02    |
| Psychotherapeutic treatment                   |                                             |                                              |                          |         |         |
| Number of psychotherapeutic treatments before baseline (no information/0/1/2), number of patients | 19/13/11/4                               | 11/6/4/0                                     | –                        | –       | 0.33    |
| Number of patients under psychotherapeutic treatment during study interval (yes/no) | 35/12                                      | 14/11                                        | –                        | –       | 0.88    |
| Cognitive-behavioural therapy                | 14                                          | 10                                           | –                        | –       | –       |
| Psychoanalytic psychotherapy                 | 1                                           | 0                                            | –                        | –       | –       |
| Psychodynamic psychotherapy                   | 7                                           | 0                                            | –                        | –       | –       |
| Other method                                  | 2                                           | 0                                            | –                        | –       | –       |
| No information regarding method              | 11                                          | 4                                            | –                        | –       | –       |

HRSD, Hamilton Rating Scale for Depression.

a. Comparing patients with relapse, no-relapse and healthy controls by using a one-way analysis of variance, except where noted.
b. Comparing patients with relapse and patients no-relapse by using the unpaired two-tailed t-test, except where noted.
c. P-values were obtained with the χ²-test.
d. Psychotherapeutic treatment during study interval was coded as yes with > 12 sessions of psychotherapy.

SPM. The three a priori defined ROIs were the bilateral amygdala, bilateral hippocampus with parahippocampal gyrus and bilateral insula, each created separately by means of the Wake Forest University PickAtlas20 tool (version 3.0; NeuroImaging Tools & Resources Collaboratory; https://www.nitrc.org/projects/wfu_pick-atlas) implemented in SPM12 according to the automated anatomical labeling atlas21 definitions. Subregions were labelled by using cytoarchitectonic probability maps, implemented in the JuBrain Anatomy Toolbox36 (version 2.2b; Forschungszentrum Jülich, Jülich, Germany; https://www.fz-juelich.de/inm/inm-7/DE/Resources/_doc/SPM%20Anatomy%20Toolbox_node.html) implemented in SPM12. A 3 × 2 analysis of covariance (ANCOVA) was computed with group (no-relapse, relapse, healthy controls) as between-participants factor, time (baseline, 2-year follow-up) as a within-participant factor, and age and gender as covariates. We investigated the relapse (no-relapse, relapse) × time (baseline, follow-up) interaction, the main effects of time and main effects of group at baseline and follow-up.
ROI analyses

Longitudinal relapse×time interaction

There was a significant relapse×time interaction (one-tailed) for the bilateral amygdala (Fig. 1(a) and (b)) and bilateral insula (Fig. 1(c) and (d)). The post hoc t-tests for changes in brain function from baseline to follow-up within groups revealed that the relapse×time interaction resulted from significant amygdala and insula activity increases within the no-relapse group, whereas within the relapse group, insula activity was reduced from baseline to follow-up. Healthy controls showed no significant changes over time (see also Supplementary Table 2).

For the hippocampus ROI, no significant relapse×time interaction effect emerged (P_{TFCE-FWE} = 0.055). There was no significant main effect of time for any of the three ROIs (all P_{TFCE-FWE} > 0.126).

Cross-sectional group differences at baseline

Supplementary Table 3 summarises the results of the between-group differences in baseline activity for all three ROIs. Briefly, a main effect of group at baseline emerged for the right amygdala, bilateral hippocampus and bilateral insula. Post hoc t-tests revealed that the no-relapse group showed hypoactivity within the left amygdala, bilateral hippocampus and bilateral insula, compared with healthy controls. Furthermore, patient groups differed in baseline activity, with higher baseline activity in the relapse group in the bilateral amygdala (Supplementary Fig. 3(a)), bilateral hippocampus (Supplementary Fig. 3(b)) and bilateral insula (Supplementary Fig. 3(c)), compared with the no-relapse group. Comparing the complete patient group with depression (no-relapse and relapse) together with healthy controls, no difference in brain function emerged in any of the three ROIs (all P_{TFCE-FWE} > 0.150).

Cross-sectional group differences at follow-up

There was no main effect of group at follow-up for any of the three ROIs (all P_{TFCE-FWE} > 0.187).

Whole-brain analyses

Longitudinal relapse×time interaction

Figure 2(a) and (b) and Supplementary Table 4 display the results of the relapse×time interaction (one-tailed) at the whole-brain level. Briefly, a significant relapse×time interaction emerged, driven by

Results

Brain function in course of depression

https://doi.org/10.1192/bjp.2021.223 Published online by Cambridge University Press
activity increases in the no-relapse group, whereas activity in the relapse group decreased from baseline to follow-up—mainly represented in the insula, temporal pole, temporal gyri, striatal and thalamic areas, as well as in the prefrontal cortex, including the anterior cingulate cortex (ACC), inferior, middle and superior frontal gyri. There was no significant main effect of time at the whole-brain level ($P_{\text{TFCE-FWE}} = 0.148$).

Cross-sectional group differences at baseline
Supplementary Table 5 presents the results of the between-group comparisons in baseline brain function at the whole-brain level. There was a significant main effect of group at baseline, resulting from significantly lower baseline activity in the no-relapse group compared with the relapse group (Supplementary Fig. 4) and healthy controls in regions involving prefrontal and temporal regions, basal ganglia, cerebellum and the precentral gyrus.

Cross-sectional group differences at follow-up
At follow-up, there was no significant main effect of group at the whole-brain level ($P_{\text{TFCE-FWE}} > 0.999$).

Additional analyses
Effects of treatments on changes in brain function
Detailed results can be found in Supplementary Results 2.1 and Supplementary Table 6. Briefly, after controlling for medical and psychotherapeutic treatments, there was still a significant relapse×time interaction for the amygdala and insula ROIs.

Relapse prediction
The results of additional analyses investigating the predictive value of baseline brain functional data compared with clinical data are described in Supplementary Results 2.2 and Supplementary Table 7. The model including both clinical and baseline brain
functional data revealed the best prediction regarding subsequent relapses compared with clinical or brain functional data alone. Significant predictors were cumulative duration of depression before baseline and baseline left insula activity.

Effects of remission status on follow-up brain activity

The division of the relapse group into two subgroups according to the remission status at follow-up resulted in \( n = 14 \) patients with relapse in full remission and \( n = 33 \) patients with relapse in current depression. The detailed results regarding the effects of remission status on follow-up brain activity can be found in Supplementary Results 2.3. Briefly summarised, there was a significant main effect of subgroup for the insula ROI (Fig. 3), resulting from lower activity in the relapse group with current depression compared with the healthy control group, as well as the no-relapse group and the relapse group in full remission.

Discussion

The present study examined brain function during negative emotion processing in the long-term course of depression in a naturalistic 2-year follow-up design. The main finding was that patients with diverging course of depression showed different changes in brain activity during negative emotion processing within the amygdala, insula and temporal and prefrontal cortex. Although the majority of patients were receiving treatment, medication dose and psychotherapy did not affect the pattern of results in the amygdala or insula. Baseline differences in amygdala, hippocampus and insula activity were detected between patient groups with different subsequent course of illness.

Changes in amygdala and insula activity

Both the amygdala and the insula are regions relevant for the detection and processing of emotionally salient stimuli. The association of the insula with the course of illness is also highlighted by a previous study that showed reduced cortical surface area of the insula to be associated with future depressive relapse. In our study, the insula appears to be most sensitive for brain functional changes during emotion processing in the long-term course of illness. Increased insula activity in the no-relapse group seems to represent a normalisation of brain function, as activity was abnormally low at baseline during the acute episode and showed no difference at follow-up compared with healthy controls. Furthermore, healthy controls also showed a descriptive tendency for activity increases. Likewise, we found increased amygdala activity in the no-relapse group in response to negative stimuli after 2 years. Accordingly, Ai et al. reported increased amygdala activity in association with symptom improvement during the encoding of positive and negative words. Combining these results, long-term remission may be associated with an increase in amygdala activity in response to emotional stimuli, independent of emotional valence. For the insula on the other hand, the changes in activity appear to be valence-specific, as we found increased activity in response to negative stimuli in patients in remission, whereas Opmeer et al. reported reduced activity in response to positive stimuli in remitters. It should be noted, however, that there are differences in types of task and control conditions across studies, limiting the comparability of the results and interpretations regarding emotional valence.

Changes in frontotemporal activity

Our whole-brain results further reveal changes within the temporal pole, orbitofrontal and middle frontal gyrus, and within the dorsal part of the ACC. The temporal pole is involved in face recognition and plays a key role in the integration of visual input with semantic information. It has been reported to produce functional responses comparable to the amygdala, and is also activated during emotionally salient stimuli. In contrast to the amygdala and insula, the temporal pole is also involved in more complex socioemotional functions. The dorsal pole activity is evoked during theory-of-mind tasks and atrophies are associated with social withdrawal, abnormal social behaviour and lack of empathy. Our results indicate that patients in full remission show increased temporal pole activity during negative emotional face processing, which may depict enhanced integration of emotional and social information. In contrast, patients with relapse or ongoing depression show decreased activity of the temporal pole, suggesting further difficulties in activating socioemotional functions. One potential mechanism might be depression-associated social withdrawal and social anhedonia leading to a decrease in social interactions and, therefore, to deficits in employing mentalising and theory-of-mind capacities. However, as theory-of-mind tasks were not used in our study, this interpretation remains to be verified by future studies using more complex socioemotional paradigms.

Effects of medication dose and psychotherapy on changes in brain activity

Corresponding with previous long-term fMRI research, treatment with psychotherapy during the study interval did not influence the pattern of results. Medication load diminished the relapse-associated changes in brain function at the whole-brain level. Therefore, activity changes could partly be influenced by medication dose effects, which would be in line with short-term treatment studies revealing brain functional changes during negative emotion processing after antidepressant pharmacotherapy. Nevertheless, within the amygdala and insula, neither psychotherapy nor medication influenced the pattern of results. This suggests that the course of illness rather than specific effects of treatments may underlie long-term changes in amygdala and insula activity.
Cross-sectional differences in brain activity

In contrast to previous studies, there was no difference in baseline amygdala, hippocampus and insula activity between the complete patient group including all patients with depression (both no-relapse and relapse) and healthy controls. Dividing the patient group into subgroups according to the course of illness revealed that patients without future relapse showed abnormally low amygdala, hippocampus and insula activity compared with healthy controls and the relapse group. This heterogeneity in baseline brain function within patients with depression may provide a rationale for the missing difference between the complete patient group and healthy controls at baseline.

Our analyses revealed that the inclusion of baseline brain functional data substantially improved the prediction of relapse based on clinical data alone. These results underline the potential of fMRI as an additional predictive marker to identify patients at high risk of relapse.

The finding of higher baseline brain activity in patients with an unfavourable subsequent course of illness is supported by short-term treatment studies that also suggest higher baseline activity of the insula and amygdala, associated with subsequent non-response to pharmacotherapy. In contrast, high psychological resilience has been found to be linked with lower amygdala activity during rest, and insula activity has been shown to differentiate between high-resilient and low-resilient individuals. The lower limbic activity detected in the no-relapse group could therefore be a function of higher resilience to subsequent depressive relapses. However, as the majority of patients included in our study was already under psychopharmaceutical treatment at baseline, lower baseline activity in the no-relapse group could also be a result of antidepressants applied before baseline. For example, studies showed that with antidepressant treatment, reductions in amygdala responses to negative stimuli occurred early, and even before the onset of mood changes, and that greater early reductions in amygdala and insula activity after antidepressant treatment were predictive for later response.

Notably, there was no difference in baseline amygdala, hippocampus and insula activity between the relapse group and healthy controls. Again, psychopharmacological effects could have masked potential differences in brain function, reducing potential limbic hyperactivity in this patient group. Thus, antidepressants could potentially have diminished limbic hyperactivity in both groups of patients with depression (no-relapse and relapse), with only the no-relapse group showing neural correlates of early response in terms of limbic hypoactivity.

Taken together, these results suggest heterogeneity in the neural correlates of depression that may be associated with later disease progression, and therefore emphasise the importance of longitudinal phenotyping.

Exploratory analyses revealed that at follow-up, only patients with current depression had abnormal insula activity compared with healthy controls and patients in full remission. Instead, patients in full remission showed no difference in limbic activity compared with healthy controls, independent of the occurrence of relapses during the study interval. This finding demonstrates the importance of taking the mood state into account when investigating the course of illness, and is in line with cross-sectional studies showing mood-congruent brain functional alterations of the limbic system only in patients with current depression. Nevertheless, the small sample size per subgroup in our exploratory investigations should be considered and, subsequently, these results should be interpreted carefully.

Strengths and limitations

The major strengths of our study are the prospective naturalistic design providing a high external validity, the long study interval covering 2 years and a careful investigation of the course of illness. Nevertheless, some limitations should be mentioned. First, although we were able to examine dose-dependent effects of pharmacotherapy, the small number of drug-free patients did not allow us to examine the effect of medication versus no medication. Second, given the nature of our paradigm, it cannot be clearly stated...
whether the findings are a result of processing of the emotional valence of the faces or face processing in general. However, the paradigm applied in this study is well-established and frequently used to investigate brain functional correlates of emotion processing.\textsuperscript{14-18}

Third, the reliability of paradigm-based fMRI is limited.\textsuperscript{36} Consequently, there is a high need for further longitudinal studies covering more participants, to improve the reliability of the results.

Implications

In summary, our study reveals long-term activity changes in emotion processing areas that are dependent on the course of illness, and point to a normalisation of brain function in remission. Our findings contribute to a more profound understanding of the brain functional correlates of conscious negative emotion processing in the context of depressive relapses, and thereby shed some light on the long-term neural trajectories of major depression. Common treatment approaches may be effective in reducing the negative bias in emotion processing.

Supplementary material

To view supplementary material for this article, please visit https://doi.org/10.1190/bjp.2021.223.

Data availability

The data that support the findings of this study are available from the corresponding author, R.R., upon reasonable request.

Author contributions

V.E., M.K., K.D., R.R. and U.D. contributed to the conception and design of the study. All authors contributed to the conduct of the study (including acquisition of data), V.E., M.K., M.K., R.R. and U.D. drafted the work and all other authors revised it critically for important intellectual content. All authors read and approved the final version of the manuscript.

Funding

The study was supported by grants from the Innovative Medizinische Forschung (grant RE111722 to R.R., grant KO437/18bK to K.D.), the German Research Foundation (grant RE849/8-1 to R.R., grants FOR2107 DA115/5-1 and DA115/5-2 to U.D.) and the Interdisciplinary Center for Clinical Research of the Medical Faculty of Münster (grant Dard/0217 to U.D.).
anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15(1): 273–89.
22 Phan KL, Wager T, Taylor SF, Liberzon I. Functional neuroanatomy of emotion: a meta-analysis of emotion activation studies in PET and fMRI. Neuroimage 2002; 16(2): 331–48.
23 Olson IR, Plotzker A, Ezzat Y. The enigmatic temporal pole: a review of findings on social and emotional processing. Brain 2007; 130(7): 1718–31.
24 Gorno-Tempini ML, Rankin KP, Woolley JD, Rosen HJ, Phengrasamy L, Miller BL. Cognitive and behavioral profile in a case of right anterior temporal lobe neurodegeneration. Cortex 2004; 40(4–5): 631–44.
25 Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception I: the neural basis of normal emotion perception. Biol Psychiatry 2003; 54(5): 504–14.
26 Heller AS, Johnstone T, Peterson MJ, Kolden GG, Kalin NH, Davidson RJ. Increased prefrontal cortex activity during negative emotion regulation as a predictor of depression symptom severity trajectory over 6 months. JAMA Psychiatry 2013; 70(11): 1181–9.
27 Picó-Pérez M, Alemany-Navarro M, Dunsmoor JE, Radua J, Albajes-Eizagirre A, Vervliet B, et al. Common and distinct neural correlates of fear extinction and cognitive reappraisal: a meta-analysis of fMRI studies. Neurosci Biobehav Rev 2019; 104: 102–15.
28 Korn CW, Bach DR. Minimizing threat via heuristic and optimal policies recruits hippocampus and medial prefrontal cortex. Nat Hum Behav 2019; 3(7): 733–45.
29 Fu CHY, Steiner H, Costafreda SG. Predictive neural biomarkers of clinical response in depression: a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. Neurobiol Dis 2013; 52: 75–83.
30 Williams LM, Korgaonkar MS, Song YC, Paton R, Eagles S, Goldstein-Piekarski A, et al. Amygdala reactivity to emotional faces in the prediction of general and medication-specific responses to antidepressant treatment in the randomized iSPOT-D trial. Neuropsychopharmacology 2015; 40(10): 2398–408.
31 Leaver AM, Yang H, Siddarth P, Vlasova RM, Krause B, St. Cyr N, et al. Resilience and amygdala function in older healthy and depressed adults. J Affect Disord 2018; 237: 27–34.
32 Waugh CE, Wager TD, Fredrickson BL, Noll DC, Taylor SF. The neural correlates of trait resilience when anticipating and recovering from threat. Soc Cogn Affect Neurosci 2008; 3(4): 322–32.
33 Godlewskka BR, Norbury R, Selvaraj S, Cowen PJ, Harmer CJ. Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients. Psychol Med 2012; 42(12): 2609–17.
34 Godlewskka BR, Browning M, Norbury R, Cowen PJ, Harmer CJ. Early changes in emotional processing as a marker of clinical response to SSRI treatment in depression. Transl Psychiatry 2016; 6(11): e957.
35 Amone D, Mickle S, Elliott R, Thomas E, Downey D, Juhasz G, et al. Increased amygdala responses to sad but not fearful faces in major depression: relation to mood state and pharmacological treatment. Am J Psychiatry 2012; 169(8): 841–50.
36 Elliott ML, Knott AR, Ireland D, Morris ML, Poulton R, Ramraha S, et al. What is the test-retest reliability of common task functional MRI measures? New empirical evidence and a meta-analysis. Psychol Sci 2020; 31(7): 792–806.
37 Eickhoff SB, Stephan KE, Mohlberg H, Grefkes C, Fink GR, Amunts K, et al. A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data. Neuroimage 2005; 25(4): 1325–35.